Unicycive Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Unicycive Therapeutics

12/08/2026 14:31

Unicycive Therapeutics Inc UNCY.OQ reported a quarterly adjusted loss of 52 cents​​ per share for the quarter ended June 30, identical to the same quarter last year.  The mean expectation of nine analysts for the quarter was for a loss of 34 cents per share. Wall Street expected results to range from -39 cents to -30 cents per share.
Reported revenue was zero​; analysts expected zero. 
Unicycive Therapeutics Inc's reported EPS for the quarter was a loss of 52 cents​.
The company reported a quarterly loss of $6.45 million.
Unicycive Therapeutics Inc shares had risen by 6.6% this quarter and lost 13.3% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 37.6% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Unicycive Therapeutics Inc is $30.00, about 83.3% above its last closing price of $5.00
This summary was machine generated from LSEG data August 12 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.34
-0.52
Missed
Mar. 31 2026 
-0.48
-0.54
Missed
Dec. 31 2025 
-0.47
-0.82
Missed
Sep. 30 2025 
-0.56
-0.33
Beat